 Stephanie Hsu
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaping | 4 | 2022 | 57 | 1.120 |
Why?
| | Electronic Nicotine Delivery Systems | 4 | 2022 | 91 | 1.070 |
Why?
| | Lung Injury | 4 | 2022 | 214 | 1.000 |
Why?
| | Budesonide | 2 | 2022 | 90 | 0.840 |
Why?
| | Adrenal Insufficiency | 1 | 2022 | 31 | 0.790 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2022 | 281 | 0.680 |
Why?
| | Protein-Losing Enteropathies | 1 | 2019 | 11 | 0.670 |
Why?
| | Focal Dermal Hypoplasia | 1 | 2019 | 5 | 0.640 |
Why?
| | Failure to Thrive | 1 | 2019 | 29 | 0.630 |
Why?
| | Growth Disorders | 1 | 2019 | 78 | 0.610 |
Why?
| | Eosinophilic Esophagitis | 1 | 2022 | 333 | 0.580 |
Why?
| | Glucocorticoids | 1 | 2019 | 570 | 0.480 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 2 | 2009 | 8 | 0.370 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2007 | 7 | 0.290 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2009 | 316 | 0.280 |
Why?
| | Airway Extubation | 2 | 2023 | 53 | 0.260 |
Why?
| | Hypercalcemia | 1 | 2004 | 21 | 0.220 |
Why?
| | Hypocalcemia | 1 | 2004 | 28 | 0.220 |
Why?
| | Child | 10 | 2023 | 20824 | 0.220 |
Why?
| | Ventilator Weaning | 1 | 2023 | 35 | 0.220 |
Why?
| | Lorazepam | 1 | 2023 | 26 | 0.210 |
Why?
| | Hyperparathyroidism | 1 | 2002 | 13 | 0.210 |
Why?
| | Adolescent | 12 | 2023 | 20197 | 0.200 |
Why?
| | Analgesia | 1 | 2023 | 93 | 0.200 |
Why?
| | Steroids | 1 | 2022 | 148 | 0.190 |
Why?
| | Retrospective Studies | 8 | 2023 | 14546 | 0.180 |
Why?
| | Child, Preschool | 6 | 2023 | 10457 | 0.180 |
Why?
| | Cystic Fibrosis | 2 | 2009 | 1061 | 0.180 |
Why?
| | Calcium | 2 | 2004 | 1173 | 0.180 |
Why?
| | Adolescent Medicine | 1 | 2020 | 34 | 0.170 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 81 | 0.160 |
Why?
| | Endocrinology | 1 | 2020 | 73 | 0.160 |
Why?
| | Growth Hormone | 1 | 2019 | 96 | 0.160 |
Why?
| | Capillaries | 1 | 2019 | 98 | 0.160 |
Why?
| | Inhalation Exposure | 1 | 2020 | 110 | 0.160 |
Why?
| | Vascular Malformations | 1 | 2019 | 51 | 0.160 |
Why?
| | Female | 16 | 2022 | 68162 | 0.150 |
Why?
| | Respiratory Insufficiency | 1 | 2022 | 316 | 0.150 |
Why?
| | Gynecology | 1 | 2020 | 174 | 0.150 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2020 | 165 | 0.140 |
Why?
| | Infant, Newborn | 3 | 2023 | 5704 | 0.140 |
Why?
| | Fontan Procedure | 1 | 2019 | 169 | 0.140 |
Why?
| | Thyrotropin | 1 | 2017 | 109 | 0.140 |
Why?
| | Epilepsies, Myoclonic | 1 | 2017 | 45 | 0.140 |
Why?
| | Humans | 19 | 2023 | 128896 | 0.140 |
Why?
| | Metabolic Syndrome | 1 | 2020 | 339 | 0.140 |
Why?
| | Phenotype | 2 | 2019 | 3059 | 0.130 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 308 | 0.120 |
Why?
| | Case-Control Studies | 1 | 2022 | 3334 | 0.120 |
Why?
| | Hypoglycemia | 1 | 2019 | 427 | 0.120 |
Why?
| | Developmental Disabilities | 1 | 2017 | 254 | 0.120 |
Why?
| | Male | 12 | 2022 | 63146 | 0.110 |
Why?
| | Testosterone | 1 | 2017 | 382 | 0.110 |
Why?
| | Hypothyroidism | 1 | 2012 | 71 | 0.100 |
Why?
| | Cohort Studies | 2 | 2019 | 5394 | 0.090 |
Why?
| | Lung | 2 | 2022 | 3925 | 0.090 |
Why?
| | Genomic Imprinting | 1 | 2009 | 33 | 0.080 |
Why?
| | Embryonic Stem Cells | 1 | 2009 | 114 | 0.080 |
Why?
| | Mutation | 4 | 2019 | 3671 | 0.080 |
Why?
| | Arthroscopy | 1 | 2009 | 211 | 0.070 |
Why?
| | Shoulder Joint | 1 | 2009 | 163 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2012 | 637 | 0.070 |
Why?
| | Nasal Mucosa | 1 | 2007 | 107 | 0.070 |
Why?
| | Cyclic AMP | 1 | 2007 | 230 | 0.070 |
Why?
| | Cartilage, Articular | 1 | 2009 | 296 | 0.060 |
Why?
| | Adult | 6 | 2023 | 35361 | 0.060 |
Why?
| | Infant | 4 | 2023 | 8994 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1045 | 0.060 |
Why?
| | Young Adult | 5 | 2023 | 12286 | 0.060 |
Why?
| | Withholding Treatment | 1 | 2023 | 69 | 0.050 |
Why?
| | Parathyroid Neoplasms | 1 | 2002 | 14 | 0.050 |
Why?
| | Parathyroid Glands | 1 | 2002 | 11 | 0.050 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2002 | 9 | 0.050 |
Why?
| | Tomography, Emission-Computed | 1 | 2002 | 65 | 0.050 |
Why?
| | Benzodiazepines | 1 | 2023 | 132 | 0.050 |
Why?
| | Morphine | 1 | 2023 | 128 | 0.050 |
Why?
| | Adenoma | 1 | 2002 | 210 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2520 | 0.040 |
Why?
| | Polymicrogyria | 1 | 2019 | 6 | 0.040 |
Why?
| | Radiography | 1 | 2002 | 863 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2002 | 473 | 0.040 |
Why?
| | Infant, Premature | 1 | 2004 | 540 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2023 | 594 | 0.040 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 1 | 2017 | 15 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2009 | 2494 | 0.040 |
Why?
| | Prognosis | 2 | 2020 | 3787 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2012 | 10239 | 0.030 |
Why?
| | Pain | 1 | 2023 | 761 | 0.030 |
Why?
| | Body Height | 1 | 2017 | 191 | 0.030 |
Why?
| | Middle Aged | 3 | 2022 | 30977 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2023 | 914 | 0.030 |
Why?
| | Time Factors | 2 | 2020 | 6568 | 0.030 |
Why?
| | Signal Transduction | 1 | 2007 | 4857 | 0.030 |
Why?
| | Body Weight | 1 | 2017 | 931 | 0.030 |
Why?
| | Ranitidine | 1 | 2012 | 14 | 0.030 |
Why?
| | Thyroid Hormones | 1 | 2012 | 54 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2009 | 3601 | 0.020 |
Why?
| | Hemangioma | 1 | 2012 | 44 | 0.020 |
Why?
| | Serum Albumin | 1 | 2012 | 145 | 0.020 |
Why?
| | Pregnancy | 1 | 2004 | 6247 | 0.020 |
Why?
| | Prednisone | 1 | 2012 | 241 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2270 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3286 | 0.020 |
Why?
| | Chromogranins | 1 | 2009 | 12 | 0.020 |
Why?
| | Shoulder Impingement Syndrome | 1 | 2009 | 7 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 783 | 0.020 |
Why?
| | Rotator Cuff | 1 | 2009 | 44 | 0.020 |
Why?
| | Clavicle | 1 | 2009 | 33 | 0.020 |
Why?
| | Shoulder Injuries | 1 | 2009 | 56 | 0.020 |
Why?
| | Rotator Cuff Injuries | 1 | 2009 | 56 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 525 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2009 | 503 | 0.020 |
Why?
| | Twins, Dizygotic | 1 | 2009 | 180 | 0.020 |
Why?
| | Siblings | 1 | 2009 | 220 | 0.020 |
Why?
| | Twins, Monozygotic | 1 | 2009 | 207 | 0.020 |
Why?
| | Brain | 1 | 2019 | 2592 | 0.020 |
Why?
| | Glucose Tolerance Test | 1 | 2009 | 356 | 0.020 |
Why?
| | Pain, Postoperative | 1 | 2009 | 227 | 0.020 |
Why?
| | Obesity | 1 | 2020 | 2844 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 2009 | 386 | 0.020 |
Why?
| | Reoperation | 1 | 2009 | 555 | 0.020 |
Why?
| | Models, Genetic | 1 | 2009 | 586 | 0.020 |
Why?
| | Alleles | 1 | 2009 | 847 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2009 | 290 | 0.020 |
Why?
| | Odds Ratio | 1 | 2009 | 1019 | 0.020 |
Why?
| | Risk Factors | 1 | 2020 | 9792 | 0.020 |
Why?
| | Recovery of Function | 1 | 2009 | 641 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2009 | 321 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2009 | 639 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2009 | 613 | 0.010 |
Why?
| | DNA Methylation | 1 | 2009 | 600 | 0.010 |
Why?
| | United States | 1 | 2020 | 13975 | 0.010 |
Why?
| | DNA | 1 | 2009 | 1406 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1206 | 0.010 |
Why?
| | Insulin | 1 | 2009 | 2311 | 0.010 |
Why?
|
|
Hsu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|